(NASDAQ: DARE) Dare Bioscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.58%.
Dare Bioscience's revenue in 2026 is -$57,130.On average, 5 Wall Street analysts forecast DARE's revenue for 2026 to be $485,162,192, with the lowest DARE revenue forecast at $140,034,444, and the highest DARE revenue forecast at $848,837,360. On average, 4 Wall Street analysts forecast DARE's revenue for 2027 to be $950,548,092, with the lowest DARE revenue forecast at $506,696,060, and the highest DARE revenue forecast at $1,414,133,548.
In 2028, DARE is forecast to generate $2,383,300,505 in revenue, with the lowest revenue forecast at $1,415,248,108 and the highest revenue forecast at $3,390,548,257.